Black Diamond Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
7analysts covering
FY Revenue (est.)
$5.6Mnext fiscal year
FY EPS (est.)
-$0.63next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Silevertinib (BDTX-1535) Frontline NSCLC Objective Response Rate (ORR) Quarterly60.0%Target: Maintain >50% ORR in larger registrational cohorts
Silevertinib (BDTX-1535) Frontline NSCLC Central Nervous System (CNS) ORR Quarterly0.9Target: Maintain high CNS efficacy to prevent brain metastases
Silevertinib (BDTX-1535) Frontline NSCLC Median Progression-Free Survival (mPFS) Quarterly15.2Target: Exceed historical benchmarks of 6-11 months
Cash, Cash Equivalents, and Investments Quarterly118.3MTarget: Sufficient to fund operations into the second half of 2028
Watch Items
- Silevertinib Phase 2 Glioblastoma (GBM) Trial ProgressTrigger: First patient dosed in May 2026; safety lead-in data expectedAction: Monitor safety profile of silevertinib in combination with temozolomide (TMZ) and enrollment velocity of the unmethylated MGMT promoter, EGFRvIII-positive cohort.
- Strategic Development Partnerships for SilevertinibTrigger: Absence of a global co-development partner for Phase 3 registrational trialsAction: Evaluate management's progress in securing a pharmaceutical partner to fund and execute pivotal Phase 3 trials in NSCLC and GBM, reducing dilution risk.
- Regulatory Pathway Alignment with the FDATrigger: FDA feedback on accelerated approval or registrational trial designAction: Track official communications regarding the registrational path for frontline EGFR non-classical mutation NSCLC based on the 15.2-month mPFS data.
Research as of 20 Jun 2026